Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184502 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TDP1LMNAPKMSIRT6 | |
| SCHEMBL222267 | 0.83 | MAPT (0.62) | ALDH1A1TDP1LMNASIRT6MAPT | |
| SCHEMBL3227183 | 0.80 | MAPT (0.68) | ALDH1A1PKMCYP19A1POLBMAPT | |
| SCHEMBL15994474 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TDP1LMNASIRT6POLB | |
| SCHEMBL23933066 | 0.77 | POLB (0.55) | ALDH1A1LMNACYP19A1POLBMCOLN3 | |
| SCHEMBL6522436 | 0.76 | SMN1; SMN2 (0.54) | ALDH1A1TDP1LMNASIRT6POLB | |
| SCHEMBL30184523 | 0.76 | SMN1; SMN2 (0.54) | ALDH1A1TDP1LMNASIRT6POLB | |
| SCHEMBL18687304 | 0.76 | ALDH1A1 (0.46) | ALDH1A1PKMCYP19A1POLBMAPT | |
| SCHEMBL23144776 | 0.76 | MAPT (0.60) | ALDH1A1TDP1LMNAPKMSIRT6 | |
| SCHEMBL6081388 | 0.76 | ALDH1A1 (0.55) | ALDH1A1TDP1LMNASIRT6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | ALDH1A1 2527/4885TDP1 412/4885LMNA 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.